Literature DB >> 12477433

The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection.

Luca G Guidotti1.   

Abstract

The aim of this study was to elucidate the molecular basis for viral clearance and liver disease in the pathogenesis of hepatitis B virus (HBV) infection. Using transgenic mice that replicate HBV at high levels in the liver as recipients of HBV-specific cytotoxic T cells (CTL), we have shown that the antiviral potential of the CTL is primarily mediated by noncytolytic mechanisms that involve the intra-hepatic production of IFN-gamma by these cells. We also showed that, following antigen recognition, HBV-specific CTL recruit antigen non-specific inflammatory cells that contribute to amplify the liver disease initiated by CTL. These results provided insight into immunological and virological processes that may lead to the development of new therapeutic strategies to terminate chronic HBV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477433     DOI: 10.1016/s0264-410x(02)00392-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

2.  Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.

Authors:  Qing Zhu; Colt Egelston; Susan Gagnon; Yongjun Sui; Igor M Belyakov; Dennis M Klinman; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

3.  Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B.

Authors:  Nusret Akpolat; Seyfettin Yahsi; Ahmet Godekmerdan; Kutbettin Demirbag; Mehmet Yalniz
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

Review 4.  Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges.

Authors:  Michael J Bouchard; Sonia Navas-Martin
Journal:  Cancer Lett       Date:  2010-12-18       Impact factor: 8.679

5.  Epidemiology of hepatitis B, C, D and G viruses and cytokine levels among intravenous drug users.

Authors:  Jianrong Li; Jing Wang; Kunlun Tian; Yixin Wang; Lei Zhang; Hanju Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

6.  Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling.

Authors:  Rebeca Burdeinick-Kerr; Dhanasekaran Govindarajan; Diane E Griffin
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity.

Authors:  Hiroyasu Ito; Tatsuya Ando; Kazuki Ando; Tetsuya Ishikawa; Kuniaki Saito; Hisataka Moriwaki; Mitsuru Seishima
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

8.  Generation of cytotoxic T cell against HBcAg using retrovirally transduced dendritic cells.

Authors:  Chuan-Lin Ding; Kun Yao; Tian-Tai Zhang; Feng Zhou; Lin Xu; Jiang-Ying Xu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

9.  Serum cytokine profile in patients with hepatitis B e antigen-negative chronic active hepatitis B and inactive hepatitis B virus carriers.

Authors:  Dimitra Dimitropoulou; Marina Karakantza; Georgios L Theodorou; Lydia Leonidou; Stelios F Assimakopoulos; Athanasia Mouzaki; Charalambos A Gogos
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

10.  Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination.

Authors:  Danming Zhu; Longchao Liu; Dan Yang; Sherry Fu; Yingjie Bian; Zhichen Sun; Junming He; Lishan Su; Liguo Zhang; Hua Peng; Yang-Xin Fu
Journal:  J Immunol       Date:  2016-03-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.